Background: Anthracycline-induced cardiomyopathy is one of the major complications that increase mortality in patients
receiving anthracycline-based chemotherapy.
Objective: To determine the incidence and risk factors of anthracycline-induced cardiomyopathy in patients with lymphoma.
Materials and Methods: A prospective study was conducted in adult patients with lymphoma at Srinagarind Hospital, Khon
Kaen University. Anthracycline-induced cardiomyopathy was defined as the presence of clinical signs of congestive heart
failure or the decrease of left ventricular ejection fraction [LVEF], or LVEF shortening, or the presence of abnormal wall
motion by echocardiography. Echocardiography was evaluated at baseline, after accumulating anthracyclines doses of at least
100 mg/m2 and after the last cycle of chemotherapy. The clinical parameters which literature has indicated as risk factors for cardiomyopathy were collected and analyzed by using the logistic regression method.
Results: In 104 patients, anthracycline-induced cardiomyopathy was found in 38 patients (36.5%). Accumulating doses of anthracyclines exceeding 300 mg/m2 and systemic hypertension were significant risk factors statistically associated with cardiomyopathies in patients with lymphoma.
Conclusion: The incidence of anthracycline-induced cardiomyopathy is modest in adult patients with lymphoma. A
moderate accumulated dose of anthracyclines and systemic hypertension were important risk factors. High-risk patients
should be closely monitored by echocardiography.

Keywords: Anthracycline-induced cardiomyopathy, Risk factors, Lymphoma